WO1997041895A3 - TREATMENT OF ASTHMA WITH TNFR-Ig - Google Patents

TREATMENT OF ASTHMA WITH TNFR-Ig Download PDF

Info

Publication number
WO1997041895A3
WO1997041895A3 PCT/EP1997/002256 EP9702256W WO9741895A3 WO 1997041895 A3 WO1997041895 A3 WO 1997041895A3 EP 9702256 W EP9702256 W EP 9702256W WO 9741895 A3 WO9741895 A3 WO 9741895A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
asthma
treatment
binding protein
tnfr
ig
Prior art date
Application number
PCT/EP1997/002256
Other languages
French (fr)
Other versions
WO1997041895A2 (en )
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

The present invention is directed to a method of combatting asthma with a composition containing an effective amount of a chimeric TNFα-binding protein which comprises the soluble part of the p55 TNF receptor and all domains except the first domain of the heavy chain constant region of a human IgG1 or IgG3 and to the use of such a chimeric TNFα-binding protein for the preparation of a medicament for the treatment of asthma.
PCT/EP1997/002256 1996-05-08 1997-05-02 TREATMENT OF ASTHMA WITH TNFR-Ig WO1997041895A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US1684296 true 1996-05-08 1996-05-08
US60/016,842 1996-05-08

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19970921849 EP0910413A2 (en) 1996-05-08 1997-05-02 TREATMENT OF ASTHMA WITH TNFR-Ig
JP53952297A JP2000510113A (en) 1996-05-08 1997-05-02 The treatment of asthma by TNFR-Ig
CA 2253557 CA2253557A1 (en) 1996-05-08 1997-05-02 Treatment of asthma with tnfr-ig
BR9708928A BR9708928A (en) 1996-05-08 1997-05-02 Treatment with TNFR-Ig Asthma
AU2776497A AU725408B2 (en) 1996-05-08 1997-05-02 Treatment of asthma with TNFR-Ig

Publications (2)

Publication Number Publication Date
WO1997041895A2 true WO1997041895A2 (en) 1997-11-13
WO1997041895A3 true true WO1997041895A3 (en) 1998-03-12

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002256 WO1997041895A3 (en) 1996-05-08 1997-05-02 TREATMENT OF ASTHMA WITH TNFR-Ig

Country Status (6)

Country Link
EP (1) EP0910413A2 (en)
JP (1) JP2000510113A (en)
KR (1) KR20000010825A (en)
CN (1) CN1233189A (en)
CA (1) CA2253557A1 (en)
WO (1) WO1997041895A3 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2316545A1 (en) * 1997-12-29 1999-07-08 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE602004013557D1 (en) * 2003-02-28 2008-06-19 Ares Trading Sa LIQUID FORMULATIONS OF TUMORNEKROSEFRAKTOR binding protein TBP-1
EP2073833A2 (en) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417563A2 (en) * 1989-09-12 1991-03-20 F. Hoffmann-La Roche Ag TNF-binding proteins
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0619372A1 (en) * 1993-03-29 1994-10-12 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Tumor necrosis factor muteins
WO1996003141A1 (en) * 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
WO1997022364A1 (en) * 1995-12-18 1997-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem FCε-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES, A METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417563A2 (en) * 1989-09-12 1991-03-20 F. Hoffmann-La Roche Ag TNF-binding proteins
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
EP0619372A1 (en) * 1993-03-29 1994-10-12 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Tumor necrosis factor muteins
WO1996003141A1 (en) * 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
WO1997022364A1 (en) * 1995-12-18 1997-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem FCε-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES, A METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AM. J. RESPIR. CELL MOL. BIOL. (1996), 14(5), 454-460 CODEN: AJRBEL;ISSN: 1044-1549, 1996 *
CHEMICAL ABSTRACTS, vol. 125, no. 1, 1 July 1996, Columbus, Ohio, US; abstract no. 8022, GATER, PAUL R. ET AL: "Inhibition of Sephadex-induced lung injury in the rat by Ro 45-2081, a tumor necrosis factor receptor fusion protein" XP002051460 *
CHEMICAL ABSTRACTS, vol. 125, no. 11, 9 September 1996, Columbus, Ohio, US; abstract no. 140442, RENZETTI, LOUIS M. ET AL: "Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways" XP002051459 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; RENZETTI L M ET AL: "Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.", XP002051462 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; RENZETTI L M ET AL: "Tumor necrosis factor ( TNF ) blockade with shTNFR-IgG1 inhibits allergic airway inflammation in mice without altering the Th1-Th2 cytokine profile.", XP002051461 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; XP002051463 *
INFLAMMATION RESEARCH 46 (SUPPL. 2). 1997. S143-S144. ISSN: 1023-3830 *
J. PHARMACOL. EXP. THER. (1996), 278(2), 847-853 CODEN: JPETAB;ISSN: 0022-3565, 1996 *
JOINT MEETING OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE CLINICAL IMMUNOLOGY SOCIETY, SAN FRANCISCO, CALIFORNIA, USA, FEBRUARY 21-26, 1997. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 9 *
MACARI, DAVID M. T. ET AL: "Priming of eosinophil recruitment in vivo by LPS pretreatment", J. IMMUNOL. (1996), 157(4), 1684-1692 CODEN: JOIMA3;ISSN: 0022-1767, 1996, XP002051457 *
P.R. GATER ET AL.: "Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.", AGENTS AND ACTIONS SUPPLEMENTS, vol. 49, 1997, pages 67 - 71, XP008059759 *
RENZETTI L ET AL: "Attenuation of allergic airway inflammation using Ro 45-2081, a TNFR -IgG1 fusion protein.", EXPERIMENTAL BIOLOGY 95, PART II, ATLANTA, GEORGIA, USA, APRIL 9-13, 1995. FASEB JOURNAL ISSN: 0892-6638, vol. 9, no. 4, 10 March 1995 (1995-03-10), pages A684, XP002051458 *

Also Published As

Publication number Publication date Type
KR20000010825A (en) 2000-02-25 application
EP0910413A2 (en) 1999-04-28 application
CA2253557A1 (en) 1997-11-13 application
JP2000510113A (en) 2000-08-08 application
WO1997041895A2 (en) 1997-11-13 application
CN1233189A (en) 1999-10-27 application

Similar Documents

Publication Publication Date Title
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
WO1998018497A3 (en) Contrast agents

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR YU

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997921849

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2253557

Country of ref document: CA

Ref document number: 2253557

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998/02238

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/009301

Country of ref document: MX

Ref document number: 1019980708961

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997921849

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980708961

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997921849

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019980708961

Country of ref document: KR